UniSa - IRIS Institutional Research Information System

PEPE, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.644
AS - Asia 7.358
EU - Europa 4.443
SA - Sud America 812
Continente sconosciuto - Info sul continente non disponibili 322
AF - Africa 123
OC - Oceania 15
Totale 28.717
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.375
HK - Hong Kong 2.597
SG - Singapore 2.078
IT - Italia 1.694
CN - Cina 1.191
UA - Ucraina 769
BR - Brasile 656
VN - Vietnam 603
DE - Germania 466
RU - Federazione Russa 343
IE - Irlanda 275
FI - Finlandia 238
FR - Francia 219
KR - Corea 185
TR - Turchia 172
CA - Canada 150
GB - Regno Unito 127
IN - India 126
SE - Svezia 99
BD - Bangladesh 91
AR - Argentina 60
JP - Giappone 58
IQ - Iraq 46
AT - Austria 43
NL - Olanda 42
MX - Messico 38
ID - Indonesia 37
PK - Pakistan 32
EU - Europa 30
ES - Italia 27
ZA - Sudafrica 24
UZ - Uzbekistan 23
CO - Colombia 22
CZ - Repubblica Ceca 22
PL - Polonia 22
EC - Ecuador 21
IL - Israele 21
JO - Giordania 20
MA - Marocco 19
TN - Tunisia 18
CL - Cile 16
CR - Costa Rica 15
VE - Venezuela 15
JM - Giamaica 14
DZ - Algeria 12
KE - Kenya 11
SA - Arabia Saudita 10
AU - Australia 9
TT - Trinidad e Tobago 9
MY - Malesia 8
PE - Perù 8
GT - Guatemala 7
PH - Filippine 7
PY - Paraguay 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
AL - Albania 6
EG - Egitto 6
IS - Islanda 6
KG - Kirghizistan 6
AZ - Azerbaigian 5
BG - Bulgaria 5
CH - Svizzera 5
HN - Honduras 5
NI - Nicaragua 5
OM - Oman 5
SC - Seychelles 5
SV - El Salvador 5
XK - ???statistics.table.value.countryCode.XK??? 5
EE - Estonia 4
KZ - Kazakistan 4
NG - Nigeria 4
PA - Panama 4
PR - Porto Rico 4
BO - Bolivia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GR - Grecia 3
LB - Libano 3
LT - Lituania 3
MD - Moldavia 3
NO - Norvegia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
SN - Senegal 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AO - Angola 2
BF - Burkina Faso 2
BH - Bahrain 2
BS - Bahamas 2
CW - ???statistics.table.value.countryCode.CW??? 2
DM - Dominica 2
GD - Grenada 2
IR - Iran 2
KH - Cambogia 2
MK - Macedonia 2
MN - Mongolia 2
PT - Portogallo 2
Totale 28.395
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.852
Hong Kong 2.592
Woodbridge 1.237
San Jose 1.233
Singapore 1.176
Ashburn 1.085
Wilmington 1.084
Jacksonville 927
Houston 925
Chandler 794
Princeton 665
Milan 636
Dallas 593
Council Bluffs 396
Beijing 381
Dong Ket 290
Dublin 268
Lauterbourg 183
Munich 176
Andover 172
The Dalles 168
Nanjing 150
Izmir 145
Santa Clara 133
Rome 130
Boardman 125
Pellezzano 125
New York 120
Naples 119
São Paulo 119
Los Angeles 117
Ho Chi Minh City 111
Mestre 107
Moscow 87
Hanoi 77
Düsseldorf 67
Fairfield 55
Chicago 54
Tokyo 52
Memphis 50
Nanchang 50
Helsinki 47
Salerno 46
Shenyang 46
Brooklyn 44
Hebei 44
Washington 42
Figino 41
Changsha 38
Orem 38
Jiaxing 37
Toronto 37
Pune 32
Turin 32
Columbus 31
Montreal 29
Nuremberg 29
San Francisco 28
Turku 28
Falls Church 27
Tianjin 26
Vienna 26
Atlanta 25
Denver 25
London 25
Norwalk 25
Boston 24
Frankfurt am Main 24
Seattle 24
Phoenix 22
Tashkent 21
Brasília 20
Warsaw 20
Amman 19
Chennai 19
Amsterdam 18
Philadelphia 18
Baghdad 17
Brno 17
Mexico City 17
Rio de Janeiro 17
Venezia 17
Cambridge 16
Bologna 15
Charlotte 15
Da Nang 15
Haiphong 15
Manchester 15
Redwood City 15
San Diego 15
Stockholm 15
Buffalo 14
Guangzhou 14
Shanghai 14
Biên Hòa 13
Fisciano 13
Mumbai 13
Ottawa 13
Paris 13
Newark 12
Totale 21.243
Salva come PNG Salva come JPEG
Nome #
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype 620
Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series 549
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors 526
Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits. 370
Abstract 3132: Single nucleotide polymorphisms (SNPs) in PD-L1 as predictive biomarkers for checkpoint inhibitor based-immunotherapy in caucasian patients with advanced NSCLC 347
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up 316
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-A in head and neck cancer cells in vitro and in vivo 307
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. 298
Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review 265
Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. 237
rs822336 as a predictive biomarker for anti-PD-1/PD-L1 immunotherapy in advanced NSCLC: Unraveling molecular mechanisms 212
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 210
A genotyping/phenotyping approach with careful clinical monitoring to manage the fluoropyrimidines-based therapy: Clinical cases and systematic review of the literature 201
Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-a genes on in vitro transformation of human mammary epithelial cells. 198
Phase I clinical study with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. 196
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. 194
A phase I-II trial of gefitinib (IRESSA) and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) 193
Adjuvant treatment of diabetic foot 192
5-Aza-2'-Deoxycitidine induces growth-inhibition and up-regulation of epidermal-growth factor receptor on human epithelial cancer-cells 191
Farsi promotori di salute: “Safe Sun Coast” 186
ADDITION OF ERLOTINIB TO FLUROPYRIMIDINE-OXALIPLATIN-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: TWO SEQUENTIAL PHASE I TRIALS. 184
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FLFOX-4) as first-line treatment of advanced gastric cancer patients. 181
Predictive factors of response to neoadjuvant chemoradiotherapy in rectal cancer patirnts. 179
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. 178
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. 177
Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. 175
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’) 175
Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. 172
8-Chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells 171
Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. 170
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54p53wt and U251p53mut glioblastoma cell lines. 170
Phase I-II study of sequential combination of XELOX and bevacizumab plus erlotinib (XELOX-TARAV) in first line colorectal patients:Run in phase I part 168
DNA index of ovarian carcinomas from 56 different patients: in vivo, in vitro studies. 167
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 165
Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1. 165
TESI DI DOTTORATO: Hereditary and familial breast and ovarian cancer: spectrum of related tumors. CANDIDATO: M.Pensabene. RELATORE: S.Pepe 165
8-Cl-cAMP in differentiation therapy: The reversal and suppression of malignancy targeting the intracellular transducing proteins of cAMP. 165
Regulation of the expression of Fc-epsilon-R in the human monocyte like cell line U937 by TPA and IgE. 165
Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom? 163
Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma 163
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. 162
Inhibition of NF-kB activity potentiates ionizing radiation and cisplatin induced cell killing of anaplastic thyroid carcinoma cells AACR Meeting Abstracts, Apr 2006; 2006: 1038. 162
Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. 161
NM23 gene expression correlates with cell growth rate and S-phase. 161
TSH-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cAMP-dependent protein kinase 161
Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. 161
Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with epidermal growth factor receptor tyrosine kinase inhibitors in human cancer cell lines. 161
Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC 161
Recombinant IFN-alfa 2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells. 160
Tumori Eredo-Familiari 160
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 160
EGF-R tyrosyne kinase as new target in melanoma treatment; Synergistic effect of IFN alpha in combination with ZD1839 )Iressa) , an EGFR tyrosine kinase inhibitor. 159
Synergistic anti-tumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. 158
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer 158
rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in advanced cancer patients treated with anti-PD-1/PD-L1 therapy 157
Oral antisense targeting protein kinase A type I causes antitumor and apoptotic effect in human cancer cells in vitro and in vivo and has cooperative activity in combination with antisense bcl-2. 157
La medicina narrativa per la prevenzione dell’ansia e dei disturbi clinici: uno studio- intervento di counseling con tirocinanti medici di oncologia 157
21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 September 2022 Verona, Italy 156
Phorbol-12-myristate-13-acetate (PMA) induces resistance of human melanoma cells to NK and LAK-mediated cytotoxicity. 156
Type-I isoform of PKA is involved in the control of cell proliferation and oncogene transformation of human mammary epithelial cells.Therapeutic implications 156
Altre Neoplasie 156
Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients 155
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. 154
Non lymphomatous clonal B-Cell populations in enlarged lymph nodes in acquired immunodeficiency syndrome. 154
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C beta inhibitor, in non-small cell lung cancer cells. 152
The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. 149
EPIGENETIC FACTORS IN HEREDITARY BREAST CANCER 149
Theophylline-induced apoptosis is paralleled by protein kinase A-dependent tissue transglutaminase activation in cancer cells. 149
TGFb inhibits rat thyroid cell proliferation without alterations in the expression of THS-induced cell cycle-related genes. Vol :pp , 148
Critical role of both p27kip1 and p21cip1/waf1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. 148
Loss of thyrotropin regulation and trasforming growth factor beta-induced growth arrest in erbB-2 overexpressing rat thyroid cells. 148
DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospectine series of 515 primary breast cancer. 147
A Specific miRNA Signature Correlates with Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 147
Abstract 3703: PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation 146
Growth inhibition of tumor cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors. 145
Bevacizumab maintenance in metastatic colorectal cancer: How long?. 145
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 143
P53 expression in non-small-cell lung-cancer. Clinical and biological correlations. 143
Reduction of RIAlpha subunit of cAMP-dependent Protein-Kinase expression induces growth-inhibition of human mammary epithelial-cells transformed by TGF-Alha, C-HA-RAS, and C-ErbB2 genes. 143
Growth arrest, apoptosis and potentiation of 5-fluorouracil and Raltitrexed cytotoxic effect induced by histone deacetylase inhibitor SAHA in colorectal cancer cells. 142
Overexpression of the RIα subunit of Protein Kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-Chloro-cyclic Adenosine 3′,5′-Monophosphate in chinese hamster ovary cells. 142
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting Protein Kinase A in combination with docetaxel and anti-EGFR-Receptor antibody on human breast cancer cell growth. 141
MEK-1 inhibitor PDO8059 potentiates apoptosis and growth inhibition induced by intereferon alpha (IFN alpha) in human epidermoid cancer cells. 141
The cancer spectrum related to hereditary and familial breast and ovarian cancers 140
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part. 140
Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines. 139
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 138
PRECLINICAL AND PHASE I STUDY OF OXALIPLATIN AND TOPOTECAN IN COMBINATION IN HUMAN CANCER. 138
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 137
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 137
Synerglstic antltumor effect by novel modified oligonucleotides targeting PKAI combined with cytotoxic drugs or monoclonal antibodies. 136
Le emergenze in Oncologia e le terape di supporto 135
Suppression of malignancy targeting the intracellular signal transducing proteins of cAMP: the use of site selective cAMP analogs, antisense strategy, and gene-transfer. 133
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling 132
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 132
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 1 EXPRESSION IN MALIGNANT MELANOMAS FROM PHOTOEXPOSED AREAS OF THE HEAD AND NECK REGION. 132
Cell ploidy in 19 Wilms tumors by flow-cytometry of cell suspensions prepared from paraffina embedded sections. 132
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 132
EGF activates an inducible survival response via the RAS -> Erk-1/2 pathway to counteract interferon-alfa-mediated apoptosis in epidermoid cancer cells. 130
Blast cells DNA content in childhood leukemias. 130
Totale 18.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.150
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.174 0 0 0 35 30 39 15 54 189 161 141 510
2022/20231.923 190 91 53 246 271 420 2 169 357 10 74 40
2023/20241.135 80 136 66 27 67 142 276 61 28 39 47 166
2024/20252.370 78 33 52 94 147 364 392 242 317 102 243 306
2025/20269.864 572 1.670 1.421 380 953 565 1.400 278 593 822 230 980
2026/20272.625 406 300 833 1.086 0 0 0 0 0 0 0 0
Totale 28.717